AbbVie (ABBV) Change in Receivables (2012 - 2026)
AbbVie (ABBV) posted quarterly Change in Receivables of -$87.0 million for Q1 2026, down 105.88% year-over-year from $1.5 billion in Q1 2025, and up 46.3% quarter-over-quarter from -$162.0 million in Q4 2025.
AbbVie (ABBV) Change in Receivables (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Change in Receivables for 15 consecutive years, with -$87.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 105.88% year-over-year to -$87.0 million; the TTM figure through Mar 2026 stood at -$76.0 million (down 113.33% YoY), while the FY2025 annual figure was $1.5 billion, up 819.81% from the prior year.
- Change in Receivables climbed to -$87.0 million in Q1 2026 per ABBV's latest filing, from -$162.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $1.5 billion in Q1 2025 and bottomed at -$387.0 million in Q4 2024.
- Historically, Change in Receivables has averaged $152.1 million across 5 years, with a median of $17.0 million in 2025.
- On a YoY basis, Change in Receivables climbed as much as 260.0% in 2024 and fell as far as 17100.0% in 2024.
- AbbVie's Change in Receivables stood at $416.0 million in 2022, then slumped by 181.49% to -$339.0 million in 2023, then fell by 14.16% to -$387.0 million in 2024, then surged by 58.14% to -$162.0 million in 2025, then surged by 46.3% to -$87.0 million in 2026.
- Business Quant data shows ABBV's Change in Receivables at -$87.0 million in Q1 2026, -$162.0 million in Q4 2025, and $156.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.37 Bn |
| Jun 30, 2026 | 1.37 Bn |
| Mar 31, 2026 | -87.00 Mn |
| Mar 31, 2026 | -87.00 Mn |
| Dec 31, 2025 | -162.00 Mn |
| Dec 31, 2025 | -162.00 Mn |
| Sep 30, 2025 | 156.00 Mn |
| Sep 30, 2025 | 156.00 Mn |
| Jun 30, 2025 | 17.00 Mn |
| Jun 30, 2025 | 17.00 Mn |
| Mar 31, 2025 | 1.48 Bn |
| Mar 31, 2025 | 1.48 Bn |
| Dec 31, 2024 | -387.00 Mn |
| Dec 31, 2024 | -387.00 Mn |
| Sep 30, 2024 | -344.00 Mn |
| Sep 30, 2024 | -344.00 Mn |
| Jun 30, 2024 | -178.00 Mn |
| Jun 30, 2024 | -178.00 Mn |
| Mar 31, 2024 | 702.00 Mn |
| Mar 31, 2024 | 702.00 Mn |